Combining atezolizumab plus bevacizumab with a CD4 Th1-inducer cancer vaccine derived from telomerase, in order to activate antitumor T cell immunity and bypass the immunosuppression in the tumor microenvironment in HCC, might increase the number of patients achieving a clinical benefit and the immunological efficacy. This evidence concerns the gene CD4 and neoplasm.